DC GRANULES

  • DC GRANULES 1
  • DC GRANULES 2
  • DC GRANULES 3
Product Description

Acetaminophen DC Granules; Amlodipine + Olmesartan Medoxomil DC Granules; Amlodipine + Perindopril DC Granules; Amlodipine + Telmisartan DC Granules; Amlodipine + Valsartan DC Granules; Amlodipine + Valsartan + Hydrochlorothiazide DC Granules; Atorvastatin DC Granules; Azithromycin DC Granules; Carvedilol DC Granules; Dapagliflozin + Metformin DC Granules (IR & XR); Empagliflozin + Linagliptin DC Granules; Empagliflozin + Linagliptin + Metformin (XR) DC Granules; Empagliflozin + Metformin DC Granules (IR & XR); Empagliflozin DC Granules; Ezetimibe + Rosuvastatin DC Granules; Finerenone DC Granules; Hydrochlorothiazide + Irbesartan DC Granules; Hydrochlorothiazide + Losartan DC Granules; Ibuprofen DC Granules; Losartan DC Granules; Memantine HCL DC Granules; Metformin DC Granules (IR & XR); Mirogabalin DC Granules; Naproxen + Esomeprazole DC Granules (MR); Paroxetine DC Granules (CR); Pregabalin DC Granules (CR); Rivaroxaban DC Granules; Sacubitril + Valsartan DC G...

Read more Show less

Nabiqasim Pharma Group

  • Country/Region:
    Pakistan
  • On CPHI since:
    2023
  • Certificates:
    3
  • Employees:
    1000 - 4999
Company types
CMO/CDMO
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Contract Manufacturer
Pharmaceutical Company (generic finished products)
View company profile
Categories
more categories Show less
Specifications
  • Details
    USP / BP / In-House / Customized Specifications
  • Selling Points
    International Approvals/Standards; Price; Prompt Delivery; Quality Service; Small Orders Accepted; We transform challenging APIs through advanced microencapsulation technology, delivering taste masking, controlled release, enteric and moisture protection, and directly compressible pellets & granules - enhancing product performance and
    improving patient compliance
  • Model
    Manufacturer / Supplier / CDMO / CMO
  • Supplied from
    Pakistan
  • Measured In
    gram; kilogram; Ton
More specifications Fewer specifications
Sales Markets
Show more Show less

Nabiqasim Pharma Group

  • Country/Region:
    Pakistan
  • On CPHI since:
    2023
  • Certificates:
    3
  • Employees:
    1000 - 4999
Company types
CMO/CDMO
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Contract Manufacturer
Pharmaceutical Company (generic finished products)
View company profile

More Products from Nabiqasim Pharma Group (4)

  • Cardiovascular

    Product Cardiovascular

    Nabiqasim offers a wide range of Cardiovascular products in combination and single ingredient including APIXABAN; RIVIROXABAN; SACUBITRIL+VALSARTAN; ROSUVASTATIN+EZETIMIBE and many others. 
  • Contract Manufacturing Operations (CMO)

    Product Contract Manufacturing Operations (CMO)

    Nabiqasim Pharma Group offers integrated Contract Development & Manufacturing Operations (CDMO) for pharmaceutical companies seeking a reliable partner for Branded Generic Formulations. Our capabilities include Prostaglandins, Laxatives/Enemas, Lyophilized Infusions, Tablets & Capsules, Liquids &am...
  • Lyophilization (ANVISA APPROVED) / Hormonal Section /Dydrogesterone (PIC/S APPROVED)

    Product Lyophilization (ANVISA APPROVED) / Hormonal Section /Dydrogesterone (PIC/S APPROVED)

    Lyophilized vials
  • Microencapsulated API (Coated Granules, Pellets & MUPS)

    Product Microencapsulated API (Coated Granules, Pellets & MUPS)

    Acetaminophen Taste Masked Coated Granules; Acetylsalicylic Acid Enteric Coated Granules / Pellets; 
    Ascorbic Acid Coated Granules; 
    Azithromycin Taste Masked Granules; 
    Ciprofloxacin Taste Masked Coated Granules; 
    Citric Acid Coated Granules;
    Clarithromycin Taste Ma...

Nabiqasim Pharma Group resources (1)

  • PIC/S and ANVISA Approval

    News PIC/S and ANVISA Approval

    Nabiqasim Pharma proudly announces the successful accreditation of its Injectable & Lyophilized Section by ANVISA and Hormonal Solid Dosage Manufacturing Section by PIC/S. 
    10 Oct 2025